These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25170285)

  • 1. Profile of pacritinib and its potential in the treatment of hematologic disorders.
    Hatzimichael E; Tsolas E; Briasoulis E
    J Blood Med; 2014; 5():143-52. PubMed ID: 25170285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.
    Singer JW; Al-Fayoumi S; Ma H; Komrokji RS; Mesa R; Verstovsek S
    J Exp Pharmacol; 2016; 8():11-9. PubMed ID: 27574472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
    Derenzini E; Younes A
    Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
    Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
    J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging treatment options for myelofibrosis: focus on pacritinib.
    Chow V; Weissman A; O'Connell CL; Mehrvar A; Akhtari M
    Onco Targets Ther; 2016; 9():2655-65. PubMed ID: 27226728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
    Jain T; Mesa R
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical potential of pacritinib in the treatment of myelofibrosis.
    Duenas-Perez AB; Mead AJ
    Ther Adv Hematol; 2015 Aug; 6(4):186-201. PubMed ID: 26288713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.
    Hart S; Goh KC; Novotny-Diermayr V; Tan YC; Madan B; Amalini C; Ong LC; Kheng B; Cheong A; Zhou J; Chng WJ; Wood JM
    Blood Cancer J; 2011 Nov; 1(11):e44. PubMed ID: 22829080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
    Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
    Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
    Tremblay D; Mascarenhas J
    Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3.
    Ghezzi C; Chen BY; Damoiseaux R; Clark PM
    Sci Rep; 2023 Jan; 13(1):1442. PubMed ID: 36697489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive review of pacritinib in myelofibrosis.
    Verstovsek S; Komrokji RS
    Future Oncol; 2015; 11(20):2819-30. PubMed ID: 26367195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.
    Grandage VL; Everington T; Linch DC; Khwaja A
    Br J Haematol; 2006 Nov; 135(3):303-16. PubMed ID: 16956345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis.
    Al-Fayoumi S; Hashiguchi T; Shirakata Y; Mascarenhas J; Singer JW
    J Exp Pharmacol; 2018; 10():9-17. PubMed ID: 29785143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.
    Furqan M; Mukhi N; Lee B; Liu D
    Biomark Res; 2013 Jan; 1(1):5. PubMed ID: 24252238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.
    Novotny-Diermayr V; Hart S; Goh KC; Cheong A; Ong LC; Hentze H; Pasha MK; Jayaraman R; Ethirajulu K; Wood JM
    Blood Cancer J; 2012 May; 2(5):e69. PubMed ID: 22829971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
    Komrokji RS; Seymour JF; Roberts AW; Wadleigh M; To LB; Scherber R; Turba E; Dorr A; Zhu J; Wang L; Granston T; Campbell MS; Mesa RA
    Blood; 2015 Apr; 125(17):2649-55. PubMed ID: 25762180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].
    Zhao YL; Liu GM; Zhang LJ; Liang WT; Cheng ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1275-9. PubMed ID: 27531815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAKs to STATs: A tantalizing therapeutic target in acute myeloid leukemia.
    Venugopal S; Bar-Natan M; Mascarenhas JO
    Blood Rev; 2020 Mar; 40():100634. PubMed ID: 31677846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
    Younes A; Romaguera J; Fanale M; McLaughlin P; Hagemeister F; Copeland A; Neelapu S; Kwak L; Shah J; de Castro Faria S; Hart S; Wood J; Jayaraman R; Ethirajulu K; Zhu J
    J Clin Oncol; 2012 Nov; 30(33):4161-7. PubMed ID: 22965964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.